IGF1R and thromboangiitis obliterans: To test the central hypothesis that IGF-IR represents not only a critical component in the pathogenesis of TAO, but can also be therapeutically targeted, two placebo-controlled, multicenter clinical trials of teprotumumab have been conducted (123, 124).